| memantine / Generic mfg. |
| Completed | 3 | 107 | Europe | Memantine-HCl | Merz Pharmaceuticals GmbH | Alzheimer's Disease | 12/08 | 12/08 | | |
| Completed | 3 | 487 | Europe | memantine, Axura | Merz Pharmaceuticals GmbH | Alzheimer's Disease | 11/09 | 11/09 | | |
NCT00857649: Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease |
|
|
| Terminated | 3 | 369 | Canada | Memantine, Ebixa®, Placebo | H. Lundbeck A/S | Alzheimer's Disease | 04/10 | 09/10 | | |
NCT00857233: Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease |
|
|
| Terminated | 3 | 297 | Canada | Memantine, Ebixa® | H. Lundbeck A/S | Alzheimer's Disease | 07/10 | 10/10 | | |
NCT01074619: Study on Cognitive Disorders of Multiple Sclerosis |
|
|
| Completed | 3 | 90 | Europe | Memantine, Placebo | University Hospital, Caen, Ministry of Health, France, H. Lundbeck A/S | Multiple Sclerosis | 03/11 | 11/11 | | |
NCT00594737: Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia |
|
|
| Completed | 3 | 17 | Canada | memantine hydrochloride, Ebixa, Namenda | Tiffany Chow, MD, H. Lundbeck A/S | Frontotemporal Dementia | 06/12 | 06/12 | | |
2006-000860-10: An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer’s Disease |
|
|
| | 3 | 40 | Europe | Ebixa, Lu 00-800, Ebixa 10 mg film-coated tablets, Ebixa 10 mg film-coated tablets | H. Lundbeck A/S | Effects of memantine treatment in institutionalised patients with Alzheimer\'s Disease. | | 09/06 | | |
| Terminated | 3 | 880 | Europe, Canada, US, RoW | Azeliragon, TTP488, Placebo | vTv Therapeutics | Alzheimer's Disease | 06/18 | 06/18 | | |
|
|
|
|
| Completed | 3 | 721 | Europe, RoW | Masitinib, AB1010, Placebo, Placebo Oral Tablet, Standard of care | AB Science | Alzheimer Disease | 12/20 | 12/20 | | |
| Completed | 3 | 130 | RoW | Akatinol Memantine 20 mg, Akatinol Memantine 10 mg | Merz Pharmaceuticals GmbH, LLC Merz Pharma, Russia | Vascular Dementia | 06/22 | 06/22 | | |
2021-002179-21: A phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzheimer's disease treated with standard of care: cholinesterase inhibitors, memantine |
|
|
| Not yet recruiting | 3 | 600 | Europe | Masitinib, AB1010, Film-coated tablet | AB Science, ABScience, AB Science, ABScience | Alzheimer's disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT00353665: Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) |
|
|
| Completed | 2/3 | 63 | Europe | Memantine (Ebixa), Ebixa, riluzole, rilutek, Placebo | University of Lisbon, H. Lundbeck A/S | Amyotrophic Lateral Sclerosis | 06/08 | 01/09 | | |
